Consensus is for FY25 revenue $5.13B. Reaffirms FY25 GAAP Operating Expenses view $4.1B-$4.4B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines reports Q2 EPS 6c vs. (9c) last year
- BeOne Medicines granted PRIME designation for BGB-16673 by EMA
- BeOne Medicines reports positive opinion from CHMP regarding TEVIMBRA
- BeOne Medicines price target raised to $345 from $321 at JPMorgan
- BeOne Medicines price target raised to $349 from $311 at RBC Capital